Objectives: The aim of this study was to compare EuroQol fivedimensional (EQ-5D) utility scores and six-dimensional health state classification (SF-6D) utility scores (derived from the 12-Item ShortForm Health Survey ) by using a large European sample of patients with stable coronary heart disease. Special attention was given to country-specific results. Methods: Data from the EURopean Action on Secondary and Primary Prevention by Intervention to Reduce Events III (EUROASPIRE III) survey were used. Patients hospitalized for a coronary artery bypass graft, percutaneous coronary intervention, acute myocardial infarction, or myocardial ischemia were interviewed and examined at least 6 months after their acute event. Health-related quality of life was assessed by using the EQ-5D and the SF-12. SF-12 outcomes were converted to SF-6D utility values, allowing comparison between both measures. Results: Both EQ-5D and SF-6D results were available for 7472 patients with coronary heart disease from 20 European countries. The measures were significantly correlated (intraclass correlation coefficient ¼ 0.536); however, large differences between the two measures remain. A total of 28.8% of the patients reported a ceiling effect on the EQ-5D instrument, whereas only 4.2% of the patients reported full health based on the SF-6D. Especially the mental component does not seem to be completely captured by the EQ-5D instrument. Furthermore, patients with worse EQ-5D outcomes were more likely to have better SF-6D results, whereas patients with better EQ-5D outcomes were more likely to have worse SF-6D results. Conclusions: Both measures are not interchangeable. Whereas the main disadvantage of the EQ-5D questionnaire is its ceiling effect, the potential advantages of SF-12 might disappear when converting the outcomes into an SF-6D utility, because of the small differences between patients.
Introduction
Patients' self-reported health-related quality of life (HRQOL) is increasingly considered an important outcome of medical treatment, especially in chronic conditions, such as coronary heart disease (CHD), in which patients are being monitored for a considerable period of time. CHD is often a cause of pain, increased anxiety, and functional and social limitations; hence, patients with CHD are likely to have an impaired HRQOL [1] [2] [3] . Many different disease-specific as well as general measures exist to assess HRQOL in patients with CHD such as the MacNew Heart Disease Health-related Quality of Life Questionnaire, the Seattle Angina Questionnaire, the Myocardial Infarction Dimensional Assessment Scale, the 36-Item Short-Form Health Survey (SF-36), the 12-Item Short-Form Health Survey (SF-12), the Health Utilities Index, and the EuroQol-5D (EQ-5D) questionnaire. Few of these HRQOL measures, however, generate a single preferencebased utility measure of health. Utilities are particularly useful in the calculation of incremental cost-effectiveness ratios for computing health benefits expressed in quality-adjusted life-years. The results of such evaluations enable decision makers to set priorities with regard to the reimbursement of health care; hence, the validity of utilities is of great importance. The EQ-5D is the most commonly used instrument to calculate utilities for costeffectiveness analysis purposes. However, an algorithm developed by Brazier and Roberts in 2004 [4] , made it possible to calculate a utility score based on the SF-12 by converting the measure into a six-dimensional health state classification (SF-6D) [4] [5] [6] . Some concern exists regarding the comparability between the utility score calculated from the EQ-5D questionnaire and the one based on the SF-12 [7] [8] [9] [10] . A recent study by Joore et al. [11] reported remarkable differences in cost-effectiveness results depending on the instrument used. Patients with mild health conditions had higher EQ-5D scores, whereas patients with severe conditions had higher SF-6D scores. This leads to better or worse cost-effectiveness outcomes depending on the HRQOL instrument used. The incomparability of the results using different instruments poses a real threat to the usefulness and credibility of cost-effectiveness analyses.
Existing literature regarding the comparison of the EQ-5D and the SF-6D in patients with CHD is scarce. Only one study reported on this comparison; however, the SF-6D scores were based on SF-36 outcomes and the sample size was relatively small (n ¼ 561) [12] . They concluded that the EQ-5D and the SF-6D are quite different from each other in patients with CHD. The aim of the current study study was to compare the EQ-5D and the SF-6D (based on the SF-12) utility scores by using a large European sample of patients with CHD, with an additional focus on country-specific results.
Methods

Coronary Sample
Analyses were based on EURopean Action on Secondary and Primary Prevention by Intervention to Reduce Events III (EURO-ASPIRE III) data, a cross-sectional survey performed in 2006-2007 across Europe. More details on this survey can be found elsewhere [13] . Briefly, patients aged between 18 and 80 years, hospitalized for coronary artery bypass graft, percutaneous coronary intervention, acute myocardial infarction, or myocardial ischemia, were retrospectively identified from diagnostic registers, hospital discharge lists, or other sources. In total, 8966 patients (participation rate ¼ 73%) were interviewed and examined at least 6 months and not later than 3 years after their initial hospital admission (median time ¼ 1.24 years). During interview, EQ-5D and SF-12v2 information was collected. HRQOL information was available for 20 EUROASPIRE III countries: Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, France, Greece, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Russian Federation, Slovenia, Spain, The Netherlands, Turkey, and the United Kingdom. Furthermore, self-reported demographic details, as well as disease information, were collected by trained research staff.
HRQOL Instruments
The EQ-5D is a commonly used, easy to complete, standardized instrument containing a descriptive part and a visual analogue scale. The former covers five dimensions, mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with three response categories each (no problems, some problems, and severe problems). The answers on these dimensions provide a simple descriptive profile, with 243 possible health states, from which an index score or utility score can be calculated. Within the current analyses, we have chosen to use the UK algorithm for all countries included. To conform to the EuroQoL guidelines, we used this most robust valuation set, because country-specific algorithms were not available for each individual country included. Theoretically, the index score can range between À0.594 (worst health state) and 1 (full health) [14] . The algorithm is based on the time trade-off technique developed by Torrance [15] . With this method, the subject can chose between two alternatives: a state of illness during a given period followed by death versus a state of perfect health for a shorter time period followed by death. The time period is varied until the subject is indifferent between the two alternatives.
The SF-12v2 is a shortened version of the SF-36, including 12 questions, with three to five answer categories each (Likert scale). The instrument covers eight dimensions: general health, physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, and mental health. Both a physical functioning component score and a mental functioning component score, ranging between 0 and 100, can be calculated by using a scoring algorithm. Lower scores represent worse and higher scores represent better self-perceived HRQOL outcomes [16] . By using an algorithm (UK version) by Brazier et al., SF-6D scores can be calculated from the SF-12 scores. The SF-6D is based on 11 SF-12 questions and combines them into six dimensions (physical functioning, role limitations, bodily pain, vitality, social functioning, and mental health); 7500 different health states can be defined, from which an index score or utility score can be calculated. The score can range between 0.296 and 1 [4] [5] [6] . The algorithm to calculate this score is based on the standard gamble technique, first described by von Neumann and Morgenstern [17] . It is based on a paired comparison in which subjects can chose between two alternatives. The first alternative has two possible outcomes: either the subject returns to perfect health with probability P or the subject dies with probability 1 À P. The second alternative leads to a certain disease state for life. The probability P can be varied until the subject is indifferent between the two alternatives. Because of the high number of different health states, many of them are not explicitly evaluated but estimated on the basis of their proximity to those states that are tested.
Statistical Analyses
Only patients with both EQ-5D and SF-12 information were included in the analyses. Analyses were performed both on European and on country-specific levels. A Wilcoxon signed rank test was performed to test whether the EQ-5D results differ significantly from the SF-6D values. Furthermore, the Spearman correlation and the intraclass correlation coefficient between EQ-5D and SF-6D outcomes and the spearman correlation between the different dimensions of the EQ-5D and the SF-6D were calculated. The ceiling effect of both measures was assessed by estimating the proportion of patients who reported to be in full health (no problems on either dimension). Analyses were performed by using IBM SPSS version 21.
Results
A total of 7472 patients with CHD completed the SF-12 as well as the EQ-5D instrument. Their mean age was 63.1 Ϯ 9.2 years. Three quarter of the patients were men, and one in four patients had received a low education. Almost 60% had a cardiac revascularization as recruiting diagnosis; 23.2% of the patients reported suffering from diabetes; 4.5% reported a history of stroke; and 13.3% reported having suffered a recurrent coronary event since the recruiting diagnosis. Table 1 gives an overview of the utility outcomes based on the patient characteristics.
Country-specific results are presented in Table 2 . The median EQ-5D values range between 0.66 (Russia) and 1.00 (Italy) depending on the country. The lowest EQ-5D value reported was À0.59, and the highest value was 1.00. About 1.8% of the patients had EQ-5D outcomes below 0, reflecting health states that are perceived worse than death. The median SF-6D values ranged between 0.66 (Spain, France, Croatia, Lithuania, Poland, Russia, Slovenia, and Turkey) and 0.80 (Cyprus, Italy, and The Netherlands), with the lowest SF-6D value being 0.35 and the highest being 1.00.
The EQ-5D and the SF-6D seemed to be significantly correlated with an overall Spearman correlation coefficient of 0.695. The intraclass correlation coefficient, although significant, was somewhat lower, with an overall value of 0.536. The correlation between the different HRQOL dimensions is reported in Table 3 . All dimensions were significantly correlated with each other. The highest correlations are seen between related dimensions such as physical functioning-mobility (r ¼ 0.446); physical functioningusual activities (r ¼ 0.504); role limitation-usual activities (r ¼ 0.390); social functioning-usual activities (r ¼ 0.403); pain-pain/ discomfort (r ¼ 0.630); mental health-anxiety/depression (r ¼ 0.551).
Overall, 28.8% (2149 of 7472) of the patients reported no problems on the EQ-5D instrument, whereas only 4.2% (311 of 7472) of the patients reported full health on the SF-6D instrument. Again, some variation was seen across countries, with the proportion of full health on the EQ-5D instrument ranging from 10.4% (Russia) to 50.9% (Italy); on the SF-6D instrument, full health was seen in 0.0% (Russia) to 15.7% (Cyprus) of the patients depending on the country. In those patients with full health on the EQ-5D, a median SF-6D of 0.86 (interquartile range 0.74-0.92) was found. Moreover, 15.6% of the patients with a full health on the EQ-5D still reported an SF-6D value below the overall median. Patients reporting no limitations on the EQ-5D still reported substantial problems on the SF-6D role limitation and vitality dimensions. Furthermore, of those patients reporting full health on the EQ-5D, 15.5% had a physical component score-12 value below the overall median and 23.0% had a mental component score-12 value below the overall median. In contrast, in those patients with full health on the SF-6D, only 4.2% of the patients reported an EQ-5D questionnaire value below the overall median. Patients with an EQ-5D value below 0 had SF-6D values ranging between 0.35 and 0.68. Only one patient reported severe problems on all the EQ-5D questionnaire dimensions, whereas none of the patients reported the worst possible SF-6D health state. Figure 1 compares the EQ-5D utilities with the SF-6D utilities according to patients' EQ-5D health profile. According to these data, patients with worse EQ-5D outcomes were more likely to have better SF-6D outcomes whereas patients with better EQ-5D outcomes were more likely to have worse SF-6D results.
Discussion
Similar to previous studies in various populations, the EQ-5D outcomes in patients with CHD are significantly correlated with SF-6D values, with intraclass correlation coefficients indicating moderate agreement between the instruments [8, 10, 18] . Moderate correlations were also found between related dimensions. Correlations found in our study were slightly lower (with the exception of those related to pain and mental health) than those reported by Brazier et al. [8] but stronger than those seen by van Stel and Buskens [12] . There remain, however, significant differences between the EQ-5D and SF-6D utility outcomes. In all EUROASPIRE III countries, the utility values differed significantly from each other, with median SF-6D utility scores being systematically lower than EQ-5D outcomes, both at country-specific level and after stratification by patient characteristics. Because of the small sample sizes on the country-specific level, and the variability in disease severity and comorbidities, caution is required when interpreting the results at a country level. It should also be noted that EQ-5D utility outcomes are based on UK preference weights, because country-specific weight were not available for all included countries.
Furthermore, a ceiling effect was observed in the EQ-5D instrument, but no floor effect was seen on either instrument (although a slight proportion of patients reported EQ-5D outcomes below 0). These results are similar to previously reported outcomes [11, 12] . One study reported on full health in the general population, with 47% of the patients having no problems on the EQ-5D and 5.8% of the patients reporting no problems on the SF-6D [7] . According to a study by Joore et al. [11] , 40% to 54% of hypertensive patients (depending on the treatment modality) report full health on the EQ-5D, whereas only 1% to 2% reported no problems on the SF-6D. A study in patients with CHD found a ceiling effect on the EQ-5D in 13.5% of the patients, whereas only 0.4% of the patients reported full health on the SF-6D [12] . Brazier et al. [8] acknowledge a possible ceiling effect of the EQ-5D and a possible floor effect of the SF-6D instrument [8] . Subanalyses in the EUROASPIRE III population revealed that patients reporting no problems on the EQ-5D still reported substantial problems on the SF-6D role limitation and vitality dimensions. This is in line with the lower correlations between the EQ-5D questionnaire dimensions and the SF-6D role limitation and vitality dimensions. Furthermore, within our population, mental problems especially are not completely captured by the EQ-5D instrument. Likewise, in the study by Brazier et al. [8] , based on seven patient groups, it was observed that those patients in full health on the EQ-5D may still experience problems in physical functioning, mental health, and vitality.
As mentioned by others, some of the differences between the instruments might be explained by the theoretical construction of the measures [8, 9, 12] . First, the EQ-5D questionnaire contains Table 1 -Utility outcomes by patient characteristics.
EQ-5D
SF-6D Notes. Values are median (IQR). All EQ-5D and SF-6D outcomes are significantly different (P o 0.001), except for patients with a history of stroke. AMI, acute myocardial infarction; CABG, coronary artery bypass graft; EQ-5D, EuroQol five-dimensional; IQR, interquartile range; PCI, percutaneous coronary intervention; SF-6D, six-dimensional health state short form (derived from the 12-Item Short-Form Health Survey). Ã Recurring coronary event after recruiting diagnosis.
only five dimensions, whereas the SF-6D captures six dimensions. In addition, the recall period is different: "today" versus "past four weeks"; however, we agree with van Stel and Buskens [12] that the influence of the recall period in the utility differences might be nonsignificant because HRQOL was measured in patients with stable CHD (6 months to 3 years after the recruiting diagnosis) [12] . Furthermore, the EQ-5D questionnaire covers five dimensions, each with three answer categories, whereas the SF-6D is based on 11 SF-12 questions, each with three to five response categories. An increase in the number of questions and answers automatically leads to a more descriptive and sensitive tool with a higher amount of possible outcomes. A patient who sometimes has frightened feelings might, for example, indicate that he or she is not anxious or depressed on the EQ-5D questionnaire, whereas on the SF-12 he or she would indicate "a little of the time" on the question whether he or she has felt downhearted and depressed. This is only one example indicating the more refined answer options of the SF-12. Conversion from the SF-12 to the SF-6D, however, is associated with some sensitivity loss, particularly due to the small range of possible utility scores. The SF-6D outcomes range between 0.296 and 1, which is almost half of the possible EQ-5D questionnaire range; hence, SF-6D outcomes are more centered to the middle and the potential difference between health states is larger when using the EQ-5D utility scores. This was also reported in an article by McDonough and Tosteson [19] , concluding that cost-effectiveness analyses using the SF-6D give less favorable cost-effectiveness results [19] . The EQ-5D outcomes, however, are very much skewed to the right; hence, the probability of having worse outcomes is rather low, and therefore the room for improvement is limited, especially in patients with a mild or largely asymptomatic condition. In contrast, the impairments associated with a mild condition might be better recognized by the SF-6D; hence, the SF-6D might be more sensitive for smaller impairments, Notes. All correlations are significant (P o 0.001). Bold indicates related dimensions. EQ-5D, EuroQol five-dimensional; SF-6D, six-dimensional health state short form (derived from the 12-Item Short-Form Health Survey).
leading to better cost-effectiveness outcomes. Indeed, the change in utility score rather than the absolute value of the score is of most importance in cost-effectiveness analyses.
In agreement with the literature, EUROASPIRE III results have indicated that patients with worse EQ-5D outcomes were more likely to have better SF-6D results, whereas patients with better EQ-5D outcomes were more likely to have worse SF-6D results [11] . Furthermore, our results indicate that disease severity or patient characteristics are not always equally captured by both instruments. In patients with diabetes, a history of stroke, or a recurrent coronary event, the proportion of patients reporting full health is lower, both using the EQ-5D and the SF-6D. Patients who are categorized as having a coronary artery bypass graft or percutaneous coronary intervention, however, were more likely to report full health on the EQ-5D but not on the SF-6D compared to patients having acute myocardial infarction or ischemia. Likewise, smokers and obese patients were less likely to report full health on the SF-6D but not on the EQ-5D questionnaire than were nonsmokers and patients with a normal weight.
Medicine has changed tremendously during the last century. New scientific insights have led to the development of several innovations regarding medication, technical procedures, and diagnostic tools. Today's society strives to provide the best possible health care; however, financial resources are limited. Therefore, the use of cost-effectiveness analyses is becoming increasingly important. Current recommendations from the National Institute for Health and Care Excellence promote the use of the EQ-5D questionnaire instrument for the calculation of quality-adjusted life-years [20] . It is important, however, to recognize the advantages and disadvantages of both the EQ-5D questionnaire and the SF-6D instrument. Although the main disadvantage of the EQ-5D questionnaire is its ceiling effect, the potential advantages of the SF-12 might disappear when converting the outcomes into an SF-6D utility score. The new fivelevel EQ-5D questionnaire might overcome some of the abovereported problems by increasing sensitivity and reducing the ceiling effects; however, further research is needed to investigate these issues [21] .
In conclusion, our study results have indicated that both utility tools are not interchangeable. In addition to the different theoretical construction of the instruments and the unequal utility range, differences in outcome can be explained by patient characteristics and disease severity. Knowledge of these inconsistencies is required when using utility values to avoid comparison of values derived from different instruments. Fig. 1 -Comparison between EQ-5D utilities and SF-6D utilities according to patients' EQ-5D health profile. EQ-5D, EuroQol five-dimensional; SF-6D, six-dimensional health state short form (derived from the 12-Item Short-Form Health Survey).
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